Table 1.
Demographic and clinical characteristics of participants.
| Elite Controllers | Non-Controllers | Healthy Donors | |
|---|---|---|---|
| Number of individuals | 06 | 07 | 09 |
| Age (years, median (IQR)) | 42 (37–52) | 37 (32–55) | 29 (27–39) |
| Body mass index BMI | 26.98 (25.4–28.4) | 23.32 (20.7–25.4) | 26.03 (22.01–30.6) |
| Gender, n (%) | |||
| Female | 4 (67%) | 2 (29%) | 6 (67%) |
| Male | 2 (33%) | 5 (71%) | 3 (33%) |
| Ethnicity, n (%) | |||
| Euro-descendant | 8 (100%) | 6 (86%) | 8 (89%) |
| Afro-descendant | 0 | 1 (14%) | 1 (11%) |
| Category Exposure, n (%) | |||
| HET | 4 (67%) | 2 (28.5%) | - |
| MSM | 2 (33%) | 3 (43%) | - |
| IDU | 0 | 2 (28.5%) | - |
| Time since HIV-1 diagnosis years (median (IQR)) | 5.6 (5.0–9.3) | 6.4 (5.8–6.9) | - |
| CD4+ T-cell count (median (IQR)) | 1190 (605.5–1370) | 726 (521–866) | - |
| CD8+ T-cell count (median (IQR)) | 1057 (810–1356) | 1295 (798–1527) | - |
| CD4/CD8+ T-cell ratio (median (IQR) | 0.99 (0.59–1.49) | 0.56 (0.4–0.72) | - |
| Viral load (copies/mL) (median (IQR)) | Undetectable | 4203 (2316–5510) | - |
| HIV-1 Subtype (%) | |||
| B | 3 (50%) | 3 (43%) | - |
| C | 3 (50%) | 4 (57%) | - |
Results were presented in median (interquartile range, IQR). Abbreviations: HET, heterosexual; MSM, men who have sex with men; IDU, injecting drug users.